Oncourologist's opinion on the results of the Carmena study. Letter to the editors

Recently published results of CARMENA study seem to eliminate cytoreductive nephrectomy from current recommendations on the treatment of metastatic renal cell carcinoma patients who are candidates for targeted antiangiogenic therapy. The article is devoted to the critical analysis of the CARMENA trial and review of previously published data. Taking into account available data cytoreductive nephrectomy should be still performed in carefully selected patients.